The invention relates to the technical field of radiopharmaceuticals and
medical imaging, in particular to an STING-targeted precursor compound, a
nuclide marker, a preparation method and application of the STING-targeted precursor compound, a
nuclide marker, a pharmaceutical composition and application of the pharmaceutical composition. The STING targeting precursor compound, the pharmaceutically acceptable form of the STING targeting precursor compound, the
nuclide marker of the STING targeting precursor compound and the pharmaceutically acceptable form of the STING targeting precursor compound have excellent in-vivo biological performance, can have high specific uptake in tumors or inflammations with high expression of
interferon stimulating factors STING, has a high target-to-non-target ratio, and can be used for preparing the target-to-non-target
tumor marker of the STING targeting precursor compound and the nuclide marker of the STING targeting precursor compound and the pharmaceutically acceptable form of the STING targeting precursor compound and the nuclide marker of the STING targeting precursor compound. And the non-specific background is low, and unnecessary radioactive injury can be reduced by lower non-target
visceral organ uptake, so that the medication safety is high.